

Transcript Details

This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: <https://reachmd.com/programs/medical-industry-feature/elevating-treatment-acne-through-patient-physician-dialogues/12040/>

ReachMD

www.reachmd.com
info@reachmd.com
(866) 423-7849

Elevating the Treatment of Acne Through Patient & Physician Dialogues

Announcer:

Welcome to ReachMD.

This medical industry feature, titled “Elevating the Treatment of Acne Through Patient and Physician Dialogues” is sponsored by Galderma Laboratories, L.P.

Presenting is Dr. Mona Gohara, a paid consultant for Galderma Laboratories, L.P.

Dr. Mona Gohara:

For the 50 million Americans living with acne, the conversation has been primarily focused on facial acne, overlooking not only other areas of the body but the effects people are experiencing beyond the skin.

Fifty-two percent of patients with facial acne also have acne on their back, shoulders and chest, and whether due to feelings of embarrassment or simply an out of sight, out of mind mentality, patients may not be forthcoming with where acne appears on their body or how painful it can be.

Additionally, those with acne on their body often feel as though it limits the activities they want to do, and some may even shy away from social interaction.

As dermatologists, we have a direct line of communication with our acne patients and can help them find the solution that delivers the results they are looking for.

For my patients with facial and truncal acne, I often recommend AKLIEF, trifarotene cream 0.005%, indicated for the treatment of acne, one of the more recent innovations to become available to prescribers and patients.

AKLIEF cream is the only prescription treatment that’s been studied and proven safe and effective for the treatment of both facial and truncal acne, and it contains the only retinoid molecule, trifarotene, that specifically targets retinoid acid receptor gamma, the most prevalent retinoid acid receptor found in the skin. The exact process by which trifarotene ameliorates acne is still unknown.

In clinical trials with AKLIEF cream, the most common adverse reactions occurring with an incidence of less than 1% were application site irritation, application site pruritus, or itching, and sunburn.

There are a lot of acne treatments out there, and it’s important to educate ourselves about all treatment options, but what’s even more important is to fully understand our patients’ experiences, and that starts with asking the right questions about their acne, even the acne we can’t see.

When we start offering solutions for achieving clearer skin on the face and trunk, we can start having meaningful impacts on our patients’ physical and emotional well-being.

Announcer:

Important Safety Information

INDICATION: AKLIEF®(trifarotene) Cream, 0.005% is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. **ADVERSE EVENTS:** The most common adverse reactions (incidence ≥ 1%) in patients treated with AKLIEF Cream

were application site irritation, application site pruritus (itching), and sunburn.

WARNINGS/PRECAUTIONS: Patients using AKLIEF Cream may experience erythema, scaling, dryness, and stinging/burning. Use a moisturizer from the initiation of treatment, and, if appropriate, depending upon the severity of these adverse reactions, reduce the frequency of application of AKLIEF Cream, suspend or discontinue use. Avoid application of AKLIEF Cream to cuts, abrasions or eczematous or sunburned skin. Use of “waxing” as a depilatory method should be avoided on skin treated with AKLIEF Cream. Minimize exposure to sunlight and sunlamps. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

©2020 Galderma Laboratories, L.P. All Rights Reserved. All trademarks are the property of their respective owners.

This program was provided in partnership with Galderma Laboratories L.P. If you missed any part of this discussion, visit ReachMD.com/IndustryFeature. This is ReachMD. Be part of the knowledge.